Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals, Inc. (AVIR) reported a third-quarter net loss of $32.2 million, compared with $42.0 million a year earlier; research and development expense was $27.1 million versus $38.3 million. In July, its Phase 3 C-BEYOND study of BEM/RZR met its primary endpoint, demonstrating statistical non-inferiority to SOF/VEL. In the 905-person modified intent-to-treat analysis, sustained virologic response was 93.9% with BEM/RZR and 94.8% with SOF/VEL. Patients without cirrhosis received eight weeks of BEM/RZR versus 12 weeks of SOF/VEL.
At September 30, Atea held $191.2 million in cash, cash equivalents and marketable securities, and used $112.3 million of operating cash during the nine months ended September 30, 2026. On November 6, it borrowed $65.0 million under a term-loan facility of up to $200.0 million; additional amounts are subject to lender discretion or specified milestones. Atea estimates its available resources, including the borrowing, will fund planned operations into mid-2028.
Atea Pharmaceuticals, Inc. (AVIR) reported third-quarter 2026 results and clinical and financing updates. Its Phase 3 C-BEYOND trial met primary and secondary endpoints, with BEM/RZR statistically non-inferior to SOF/VEL in the modified intent-to-treat population: Week 24 SVR was 93.91% versus 94.75%, respectively, among 905 patients.
Quarterly net loss was $32.162 million, compared with $42.049 million in third quarter 2025; research and development expense was $27.091 million versus $38.347 million. Cash, cash equivalents and marketable securities totaled $191.199 million at September 30, 2026, versus $301.830 million at December 31, 2025. Atea announced a Hercules Capital credit facility for up to $200 million; $65 million was drawn at closing on November 6, 2026. It may access up to $135 million more, subject to specified milestones and other loan terms. Based on its current operating plan and current cash, cash equivalents and investments, Atea anticipates funding planned operations into mid-2028. C-FORWARD topline results are expected in early 2027 and are expected to support an NDA submission targeted for mid-2027. AT-587’s Phase 1 study advanced to multiple ascending doses, with a proof-of-concept study anticipated in the first half of 2027.
Atea Pharmaceuticals (AVIR) entered into a senior secured loan agreement with Hercules Capital, as agent, and the lenders, providing for term loans with aggregate principal of up to $200.0 million. The company drew $65.0 million on November 6, 2026. Later tranches are subject to conditions: Tranche 2 includes successful completion of the ongoing Phase 3 BEM/RZR trial before a specified date in the second half of 2027; Tranches 3 and 4 depend on financing and development or commercialization milestones, and Tranche 5 is available at the lenders’ sole discretion.
The loans mature on November 1, 2031, carry a floating annual interest rate equal to the greater of the prime rate reported in The Wall Street Journal plus 2.35% or 9.35%, and are interest-only for 48 months. The company owes a $650,000 upfront fee, with an additional fee equal to 1.00% of any advance under Tranches 2 through 5. The loans are secured by substantially all company assets, including intellectual property. The agreement includes cash and BEM/RZR revenue covenants and allows lenders to accelerate obligations following an event of default.
Atea Pharmaceuticals, Inc. (AVIR) is the issuer whose common stock is covered by a joint beneficial-ownership report from Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. The reporting persons report beneficial ownership of 4,814,700 shares, or 6.0%, and shared voting and dispositive power over that amount, with no sole voting or dispositive power.
Tang Capital Management is the general partner of Tang Capital Partners and Tang Capital Partners International. Kevin Tang is the manager of Tang Capital Management and chief executive officer of Tang Capital Partners III and Tang Capital Partners IV. The reporting persons state that the shares are no longer held with a purpose or effect of changing or influencing control of Atea Pharmaceuticals, and cite Rule 13d-1(h) for the Schedule 13G filing.
Atea Pharmaceuticals is a late-stage antiviral developer reporting continued operating losses while advancing its HCV and HEV programs. For the three months ended June 30, 2026, it recorded a net loss of $32.9 million compared with $37.2 million a year earlier; for the first six months, the net loss was $78.4 million.
Cash, cash equivalents and marketable securities totaled $219.5 million as of June 30, 2026, which the company believes will fund planned operations through 2027, including completion of its Phase 3 HCV program. Second-quarter research and development expense was $28.2 million and general and administrative expense was $6.9 million, with G&A down year over year.
The lead HCV regimen, a fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR), achieved statistical non-inferiority to sofosbuvir/velpatasvir in the Phase 3 C-BEYOND trial, including a 93.9% sustained virologic response rate in the modified intent-to-treat population. Enrollment in the second Phase 3 trial, C-FORWARD, is complete, with topline data expected early in the first quarter of 2027 and an FDA New Drug Application targeted for the second quarter of 2027 if results are positive. Atea also initiated a Phase 1 trial of AT-587 for hepatitis E virus and maintains an unused $200 million at-the-market equity facility.
Atea Pharmaceuticals reported second quarter 2026 results and a major clinical milestone. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for hepatitis C met its primary and secondary endpoints in a real-world-like North American population, supporting a potential best-in-class, 8‑week regimen for most non‑cirrhotic patients. A second Phase 3 trial, C-FORWARD, completed enrollment of more than 880 patients across 17 countries, with topline data expected in early Q1 2027 and a potential US NDA submission for BEM/RZR targeted for Q2 2027.
For the quarter ended June 30, 2026, Atea reported a net loss of $32.9 million, compared with $37.2 million a year earlier, as operating expenses declined. Research and development expense was $28.2 million versus $32.3 million, and general and administrative expense was $7.0 million versus $9.1 million, reflecting lower stock-based compensation and professional fees. Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025, with working capital of $200.5 million and no debt-like liabilities indicated.
Atea also initiated a first‑in‑human Phase 1 trial of AT-587 for chronic hepatitis E in immunocompromised patients, addressing an area with no approved antiviral therapies and significant unmet medical need.
Atea Pharmaceuticals director Bruno Lucidi reported equity compensation activity centered on stock awards rather than open‑market trades. He exercised 29,600 restricted stock units into Common Stock and held 142,350 Common shares directly afterward. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, all subject to time‑based vesting over the coming year.
Atea Pharmaceuticals director Franklin M. Berger increased his equity exposure through compensation-related awards and an RSU vesting event. On June 18, 2026, 29,600 restricted stock units converted into an equal number of common shares, bringing his direct common stock holdings to 536,097 shares.
He also received a stock option for 37,700 shares at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and expiring on June 17, 2036. In addition, he was granted 26,700 new restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation. On June 18, 2026, he was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026, and are fully vested on June 18, 2027, if he continues serving the company.
He also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Barbara Gayle Duncan increased her equity stake through routine compensation-related transactions. On June 18, 2026, previously granted restricted stock units converted into 29,600 shares of common stock, bringing her direct holdings to 92,350 shares.
She also received new grants covering 37,700 stock options with a $4.36 exercise price, vesting in twelve equal monthly installments through June 18, 2027, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.